|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Even if proprotein convertase subtilisin/kexin type 9 inhibitors have replaced lipoprotein apheresis in many patients, lipoprotein apheresis still is an important option in homozygous familial hypercholesterolemia, progressive atherosclerosis or when removal of lipoprotein(a) is indicated.
|
31782556 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein associated with atherosclerotic cardiovascular disease.
|
31130489 |
2019 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
|
31655942 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
|
31577611 |
2019 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Objective- Lp(a) [lipoprotein(a)] is a well-described risk factor for atherosclerosis, but Lp(a)-associated risk may vary by race/ethnicity.
|
30727753 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review summarizes recent findings of the roles played by ATX, LPA and LPA receptors (LPARs) in atherosclerosis and calcific aortic valve disease.
|
30928673 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The European Atherosclerosis Society recommends screening for elevated lipoprotein(a) levels in high-risk patients.
|
31111240 |
2019 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic vascular disease.
|
29912783 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we performed the first exploratory analysis of PLPP3, LPA, and LPA receptors (LPARs 1-6) in human atherosclerosis.
|
30003117 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.
|
29122817 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This may include measurement of inflammatory markers, subclinical indicators of atherosclerosis (e.g., coronary artery calcium and ankle brachial index), urinary albumin/creatinine ratio, and the level of lipoprotein (a).
|
29556802 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) Lp(a) is a cholesterol-rich, LDL-like particle that is independently associated with an increased risk for ischemic heart disease, atherosclerosis, thrombosis, and stroke.
|
28608522 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is an inherited atherogenic lipoprotein and an independent risk factor for atherosclerotic cardiovascular disease; however, its clinical role remains limited.
|
28801030 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) accelerated the progression of atherosclerosis in patients with end-stage renal disease.
|
30071823 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Lipid levels were measured and a proteomic approach was used to quantify proteins in the livers of mice with an elevated low-density lipoprotein (LDL) and the presence of lipoprotein(a) [Lp(a)] but no atherosclerosis.
|
30596094 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent data have suggested an important role of lipoprotein (a) [Lp(a)] and proprotein convertase substilisin/kexin type 9 (PCSK9) in the development of atherosclerotic cardiovascular disease (ASCVD) in both general population and family hypercholesterolemia (FH), while the relation of Lp(a) to PCSK9 has not been examined.
|
29129821 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, atherosclerosis in heterozygous FH differs in several respects from that of homozygotes, notably the lack of aortic root involvement and in its multifactorial aetiology, with raised LDL cholesterol, male gender, low HDL cholesterol and raised lipoprotein (a) all contributing to its clinical expression.
|
30064057 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In these patients, low adiponectin and high lipoprotein(a) levels are found which are known to be associated with endothelial dysfunction, atherosclerosis and coronary artery disease.
|
27007665 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, we find that LPA risk genotypes confer greater relative risk for incident atherosclerotic cardiovascular diseases compared to directly measured Lp(a), and are significantly associated with measures of subclinical atherosclerosis in African Americans.
|
29973585 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Individuals with elevated lipoprotein (a) have a high life-time burden of atherosclerotic cardiovascular disease.
|
29609758 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our objective is to review the role of these agents in the management of patients at high ACVD risk and introduce new and (re)-emerging drugs targeting atherogenic lipoproteins such as LDL (inclisiran, bempedoic acid, etc.), remnant-like particles (fibrates, volanesorsen, and angiopoietin-like protein-3 (ANGPTL3) inhibitors), and lipoprotein(a) (AKCEA-APO[A]L<sub>RX</sub> ).
|
29737015 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated an association between lipoprotein (a) [Lp(a)] levels and atherosclerosis in human immunodeficiency virus (HIV)-seropositive women.
|
30012717 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 1987-1989, the Atherosclerosis Risk in Communities study measured plasma lipoprotein(a) in 13,683 participants aged 45-64 years, without a history of AAA surgery.
|
29182987 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] level is a novel risk factor for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia (FH), while its impact on the different sites of arteries remains undetermined.
|
29603377 |
2018 |